Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2023-06-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-47715 |
| _version_ | 1827935338068180992 |
|---|---|
| author | Müzeyyen Aslaner Ak Ayfer Gedük İbrahim Halil Açar Merve Gökçen Polat Cenk Sunu Ali Zahit Bolaman Tuba Hacıbekiroğlu Birol Güvenç Şehmus Ertop |
| author_facet | Müzeyyen Aslaner Ak Ayfer Gedük İbrahim Halil Açar Merve Gökçen Polat Cenk Sunu Ali Zahit Bolaman Tuba Hacıbekiroğlu Birol Güvenç Şehmus Ertop |
| author_sort | Müzeyyen Aslaner Ak |
| collection | DOAJ |
| description | Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting.
Materials and Methods: A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion needs were recorded before treatment and at 12 months, 24 months, 36 months, and 48 months of treatment.
Results: At the 36-month (p=0.025) and 48-month (p=0.022) visits, epoetin alfa yielded significantly higher hemoglobin levels compared to darbepoetin alfa. Transfusion needs were also significantly lower with epoetin alfa compared to darbepoetin alfa at 24 months (p=0.012) and in the low-risk group compared to the intermediate-risk group at 24 months (p=0.018), 36 months (p=0.025), and 48 months (p<0.001). Treatment response rates at the 24-month, 36-month, and 48-month visits in the epoetin alfa (43.0%, 33.6%, and 27.1%), darbepoetin alfa (29.9%, 22.7%, and 16.5%), low-risk (39.3%, 30.0%, and 26.0%), and intermediate-risk (29.6%, 24.1%, and 11.1%) groups were lower than those obtained at 12 months, and the values differed significantly for the 36-month and 48-month visits with values ranging from p<0.05 to p<0.001.
Conclusion: This real-life long-term ESA extension study investigated the clinical efficacy of epoetin alfa and darbepoetin alfa for up to 48 months, revealing that treatment efficacy reached a plateau starting from the 24th month of therapy with a continuing decrease in treatment response rates regardless of treatment type, risk status, or gender. Nonetheless, significantly higher hemoglobin levels and marked improvement in transfusion needs were evident in epoetintreated patients compared to darbepoetin-treated patients and in the low-risk group compared to the intermediate-risk group. |
| first_indexed | 2024-03-13T07:53:44Z |
| format | Article |
| id | doaj.art-119cab3394ef41ee9f63074b936f7071 |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-03-13T07:53:44Z |
| publishDate | 2023-06-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-119cab3394ef41ee9f63074b936f70712023-06-02T08:17:36ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632023-06-014029210010.4274/tjh.galenos.2023.2022.0437Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life DataMüzeyyen Aslaner Ak0https://orcid.org/0000-0001-6621-3138Ayfer Gedük1https://orcid.org/0000-0001-9556-8915İbrahim Halil Açar2https://orcid.org/0000-0002-8657-1407Merve Gökçen Polat3https://orcid.org/0000-0001-9797-3922Cenk Sunu4https://orcid.org/0000-0002-6513-6211Ali Zahit Bolaman5https://orcid.org/0000-0003-0651-5462Tuba Hacıbekiroğlu6https://orcid.org/0000-0003-1814-5972Birol Güvenç7https://orcid.org/0000-0001-7641-5673Şehmus Ertop8https://orcid.org/0000-0001-8771-7343Zonguldak Bülent Ecevit University Faculty of Medicine, Department of Hematology, Zonguldak, TürkiyeKocaeli University Faculty of Medicine, Department of Hematology, Kocaeli, TürkiyeÇukurova University Faculty of Medicine, Department of Hematology, Adana, TürkiyeKocaeli University Faculty of Medicine, Department of Hematology, Kocaeli, TürkiyeSakarya Training and Research Hospital, Clinic of Hematology, Sakarya, TürkiyeAdnan Menderes University Faculty of Medicine, Department of Hematology, Aydın, TürkiyeSakarya Training and Research Hospital, Clinic of Hematology, Sakarya, TürkiyeÇukurova University Faculty of Medicine, Department of Hematology, Adana, TürkiyeZonguldak Bülent Ecevit University Faculty of Medicine, Department of Hematology, Zonguldak, TürkiyeObjective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk or intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion needs were recorded before treatment and at 12 months, 24 months, 36 months, and 48 months of treatment. Results: At the 36-month (p=0.025) and 48-month (p=0.022) visits, epoetin alfa yielded significantly higher hemoglobin levels compared to darbepoetin alfa. Transfusion needs were also significantly lower with epoetin alfa compared to darbepoetin alfa at 24 months (p=0.012) and in the low-risk group compared to the intermediate-risk group at 24 months (p=0.018), 36 months (p=0.025), and 48 months (p<0.001). Treatment response rates at the 24-month, 36-month, and 48-month visits in the epoetin alfa (43.0%, 33.6%, and 27.1%), darbepoetin alfa (29.9%, 22.7%, and 16.5%), low-risk (39.3%, 30.0%, and 26.0%), and intermediate-risk (29.6%, 24.1%, and 11.1%) groups were lower than those obtained at 12 months, and the values differed significantly for the 36-month and 48-month visits with values ranging from p<0.05 to p<0.001. Conclusion: This real-life long-term ESA extension study investigated the clinical efficacy of epoetin alfa and darbepoetin alfa for up to 48 months, revealing that treatment efficacy reached a plateau starting from the 24th month of therapy with a continuing decrease in treatment response rates regardless of treatment type, risk status, or gender. Nonetheless, significantly higher hemoglobin levels and marked improvement in transfusion needs were evident in epoetintreated patients compared to darbepoetin-treated patients and in the low-risk group compared to the intermediate-risk group.https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-47715myelodysplastic syndromelow-riskintermediate-1- riskepoetin alfadarbepoetin alfalong-termtreatment responseduration of responsetransfusion dependence |
| spellingShingle | Müzeyyen Aslaner Ak Ayfer Gedük İbrahim Halil Açar Merve Gökçen Polat Cenk Sunu Ali Zahit Bolaman Tuba Hacıbekiroğlu Birol Güvenç Şehmus Ertop Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data Turkish Journal of Hematology myelodysplastic syndrome low-risk intermediate-1- risk epoetin alfa darbepoetin alfa long-term treatment response duration of response transfusion dependence |
| title | Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data |
| title_full | Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data |
| title_fullStr | Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data |
| title_full_unstemmed | Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data |
| title_short | Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data |
| title_sort | long term efficacy of erythropoiesis stimulating agents in patients with low risk or intermediate 1 risk myelodysplastic syndrome multicenter real life data |
| topic | myelodysplastic syndrome low-risk intermediate-1- risk epoetin alfa darbepoetin alfa long-term treatment response duration of response transfusion dependence |
| url | https://tjh.com.tr/jvi.aspx?pdir=tjh&plng=eng&un=TJH-47715 |
| work_keys_str_mv | AT muzeyyenaslanerak longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT ayfergeduk longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT ibrahimhalilacar longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT mervegokcenpolat longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT cenksunu longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT alizahitbolaman longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT tubahacıbekiroglu longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT birolguvenc longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata AT sehmusertop longtermefficacyoferythropoiesisstimulatingagentsinpatientswithlowriskorintermediate1riskmyelodysplasticsyndromemulticenterreallifedata |